Press / Publications

Jan Zimmer´s work in the field of nanodmedicine, contributes to the development of innovative biomaterials for targeted drug delivery and offers promising approaches for future therapeutic applications in gene therapy and cancer research.

The Fraunhofer Institute for Microengineering and Microsystems IMM will par-ticipate as an exhibitor at the international trade fair Hyvolution 2026. The three-day leading event for the hydrogen sector will take place from January 27 to 29, 2026, at Paris Expo Porte de Versailles. The Fraunhofer IMM team will welcome trade visitors at booth N47 in Hall 1, where it will showcase its latest solutions for hydrogen production and power-to-gas processes.

After two years of research and development work, the German-Chilean Power-to-MEDME-R&D project has been successfully completed. The Fraunhofer Institute for Energy Economics and Energy System Technology IEE and its project partners have developed key technological, economic, and systemic foundations for the sustainable production of green hydrogen and its derivatives methanol and dimethyl ether (DME) in Chile. The results show that Chile offers excellent conditions for cost-efficient, cli-mate-neutral production with a high potential for local use and export in an interna-tional comparison.

The team of authors received the GMM Literature Prize 2025 for their publication on a novel system for real-time analysis of nanoparticles during their synthesis. The prize was presented to the lead author, Ebrahim Taiedinejad, at the MikroSystemTechnik Kongress 2025.

With flowDLS, Fraunhofer IMM has developed a system based on dynamic light scattering (DLS) that measures particle sizes in real time. What makes flowDLS special? Read more in our Newsletter "FlowDLS: Real-time precision in nanoparticle analysis".

People being monitored for chronic kidney disease or heart failure often have high levels of potassium in their blood (hyperkalemia) due to impaired renal potassium excretion caused by kidney damage or by medications. But such medications interfere with urinary potassium excretion. This electrolyte imbalance can be life-threatening and thus must be closely monitored. In collaboration with French start-up Ki'tech, researchers at the Fraunhofer Institute for Microengineering and Microsystems IMM want to revolutionize patient monitoring with a minimally invasive solution that measures biomarkers, including potassium, in the subcutaneous interstitial fluid.

We generally feel safe at home. It is where we have designed our sur- roundings according to our preferences and chosen products to the best of our knowledge. But can we truly be sure that these products pose no threat to our health? In the EU-funded project MetrIAQ, Fraunhofer IMM collaborated with several national and international partners to develop novel microcapsules as reference materials for quality assurance in emission testing for the health evaluation of building products.

In his work in the field of reactive intermediates, Lars Gössl focuses on quantity-optimized and demand-driven production of various organozinc halides as well as their conversion into synthetically relevant compounds.

Ammonia has been traditionally known for fertilizer production. In the future, it could also play a key role in the Energy Transition as an efficient source of hydrogen and a climate-friendly substitute for fossil fuels since it can be produced from nitrogen and hydrogen with zero carbon emissions. Furthermore, ammonia offers a wealth of advantages in terms of transportation and storage. The Fraunhofer Institute for Microengineering and Microsystems IMM is working on a space-saving, efficient and, above all, decentralized ammonia cracking technology in numerous research projects.

Fraunhofer IMM, part of the globally renowned Fraunhofer-Gesellschaft, today announced the signing of a Memorandum of Understanding (MoU) with CATUG, Basel, Switzerland. This strategic collaboration will drive joint research and development initiatives, particularly in the fields of nucleic acids and nanoparticle technology. CATUG is a pioneering contract service provider in RNA therapeutics and LNP formulations. The collaboration between Fraunhofer IMM and CATUG will leverage their combined expertise in sustainable technologies, scalable nanoformulation systems, and advanced nanoanalytics. Together, the partnership aims to accelerate innovation in therapeutic solutions, particularly in RNA and lipid nanoparticle (LNP) formulations.